Hepatitis C virus in vitro replication is efficiently inhibited by acridone Fac4

Area of Science:

• Virology
• Medicinal Chemistry
• Drug Discovery

Background:

• Hepatitis C virus (HCV) infects 170 million globally, with current treatments being costly and genotype-dependent.
• Acridones, natural compounds, show promise for antiviral action against HCV.
• Developing novel, effective, and affordable HCV treatments remains a priority.

Purpose of the Study:

• To screen 14 synthetic acridones for their efficacy against the Hepatitis C virus life cycle.
• To evaluate the antiviral potential of promising acridone derivatives, specifically Fac4.
• To elucidate the mechanism of action of Fac4 against HCV.

Main Methods:

• Screening of 14 synthetic acridones using a Huh7.5 cell line with an HCV genotype 2a replicon.
• Assessing cell viability (MTT assay) and viral replication (luciferase assay) after compound incubation.
• Further evaluation of Fac4's effect on HCV replication, entry, and release in HCVcc-infected cells.

Main Results:

• Acridone Fac4 inhibited >90% of HCV replication at 5 µM without affecting cell viability.
• Fac4 demonstrated ~70% inhibition of HCV replication and ~80% inhibition of viral release, with no impact on virus entry.
• Fac4 showed no inhibitory effect on genotype 3 replication and did not inhibit NS5B polymerase activity or IRES-driven translation.

Conclusions:

• Fac4 exhibits significant antiviral activity against Hepatitis C virus, particularly in replication and release stages.
• While its precise mechanism requires further investigation, Fac4's ability to intercalate into dsRNA is noted.
• Fac4 represents a promising lead compound for the development of novel anti-HCV therapeutics.